TY - JOUR T1 - A Statistical Framework to Identify Cell Types Whose Genetically Regulated Proportions are Associated with Complex Diseases JF - medRxiv DO - 10.1101/2021.02.25.21252462 SP - 2021.02.25.21252462 AU - Wei Liu AU - Wenxuan Deng AU - Ming Chen AU - Zihan Dong AU - Biqing Zhu AU - Zhaolong Yu AU - Daiwei Tang AU - Maor Sauler AU - Louise V. Wain AU - Michael H. Cho AU - Naftali Kaminski AU - Hongyu Zhao Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252462.abstract N2 - Finding disease-relevant tissues and cell types can facilitate the identification and investigation of functional genes and variants. In particular, cell type proportions can serve as potential disease predictive biomarkers. Here, we introduce a novel statistical framework, cell-type Wide Association Study (cWAS), that integrates genetic data with transcriptomics data to identify cell types whose genetically regulated proportions (GRPs) are disease/trait-associated. On simulated and real GWAS data, cWAS showed substantial statistical power with newly identified significant GRP associations in disease-associated tissues. More specifically, GRPs of endothelial and myofibroblasts in lung tissue were associated with Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease, respectively. For breast cancer, the GRP of blood CD8+ T cells was negatively associated with breast cancer (BC) risk as well as survival. Overall, cWAS is a powerful tool to reveal cell types associated with complex diseases mediated by GRPs.Competing Interest StatementN.K. served as a consultant to Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Theravance, LifeMax, Three Lake Partners, Optikira, Astra Zeneca, Augmanity over the last 3 years, reports Equity in Pliant and a grant from Veracyte and Boehringer Ingelheim and non-financial support from MiRagen and Astra Zeneca. N.K. as IP on novel biomarkers and therapeutics in IPF licensed to Biotech. M.H.C. has received grant support from GSK and Bayer, consulting or speaking fees from Genentech, AstraZeneca, and Illumina. L.V.M. holds a GSK/British Lung Foundation Chair in Respiratory Research.Funding StatementPart of the this work was supported by funding from NIH grant R01GM134005 and NSF grant DMS1902903 to H.Z., NHLBI grants R01HL127349, R01HL141852, U01HL145567, UH2HL123886 to N.L. and a generous gift from Three Lakes Partners to N.K. M.H.C. was supported by R01HL135142, R01 HL137927, R01 HL089856, R01 HL147148. The research was partially supported by the NIHR Leicester Biomedical Research Centre; the views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This manuscript is a mainly methodology paper. The data used in this manuscript is all public available. The research has no procedure related to collecting human subject data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResult files and corresponding code will be available upon acceptance of the manuscript. ER -